INT83205

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 1.14
Pain Relevance 4.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Prkca) endoplasmic reticulum (Prkca) enzyme binding (Prkca)
protein complex (Prkca) cytoplasm (Prkca) cytosol (Prkca)
Anatomy Link Frequency
hippocampus 3
cerebellum 1
Prkca (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 15 100.00 Very High Very High Very High
Hippocampus 14 100.00 Very High Very High Very High
antagonist 57 99.64 Very High Very High Very High
Morphine 24 98.36 Very High Very High Very High
addiction 8 98.00 Very High Very High Very High
Clonidine 11 97.76 Very High Very High Very High
Brush evoked pain 3 97.64 Very High Very High Very High
Thermal hyperalgesia 3 97.20 Very High Very High Very High
cerebral cortex 7 96.24 Very High Very High Very High
narcan 2 94.60 High High
Disease Link Frequency Relevance Heat
Morphine Dependence 8 98.36 Very High Very High Very High
Neuropathic Pain 5 97.64 Very High Very High Very High
Hyperalgesia 3 97.20 Very High Very High Very High
Targeted Disruption 2 77.00 Quite High
Reprotox - General 1 2 12.40 Low Low
Endometriosis (extended) 8 9.04 Low Low
Adenocarcinoma 9 5.00 Very Low Very Low Very Low
Cognitive Disorder 7 5.00 Very Low Very Low Very Low
Cancer 7 5.00 Very Low Very Low Very Low
Depression 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The membrane PKC activity was apparently enhanced in striatum but decreased in cerebellum and hippocampus. (3) PKC inhibitor was found to prevent the development of morphine dependence. (4) These changes described above were not observed in mice treated with naloxone 30 min prior to daily morphine injection.
Negative_regulation (decreased) of Negative_regulation (inhibitor) of PKC in hippocampus associated with addiction, narcan, hippocampus and morphine
1) Confidence 0.43 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016940 Disease Relevance 0.25 Pain Relevance 0.96
Spinally administered protein kinase C (PKC) inhibitors also decrease the synergism to addition.
Negative_regulation (decrease) of Negative_regulation (inhibitors) of PKC associated with kinase c
2) Confidence 0.43 Published 1999 Journal Biochem. Pharmacol. Section Abstract Doc Link 10424770 Disease Relevance 0 Pain Relevance 1.82
It should be noted that a single i.t. injection of BDNF produced a long-lasting thermal hyperalgesia and tactile allodynia in normal mice, and these responses were abolished by i.t. pre-treatment with either a Trk-dependent tyrosine kinase inhibitor K-252a or a selective protein kinase C (PKC) inhibitor Ro-32-0432.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of PKC associated with brush evoked pain, kinase c and thermal hyperalgesia
3) Confidence 0.31 Published 2005 Journal J. Neurochem. Section Abstract Doc Link 15836617 Disease Relevance 0.64 Pain Relevance 0.91
The membrane PKC activity was apparently enhanced in striatum but decreased in cerebellum and hippocampus. (3) PKC inhibitor was found to prevent the development of morphine dependence. (4) These changes described above were not observed in mice treated with naloxone 30 min prior to daily morphine injection.
Negative_regulation (decreased) of in cerebellum Negative_regulation (inhibitor) of PKC in hippocampus associated with addiction, narcan, hippocampus and morphine
4) Confidence 0.15 Published 1998 Journal Yao Xue Xue Bao Section Abstract Doc Link 12016940 Disease Relevance 0.25 Pain Relevance 0.96
Inhibition of PKC Blocks the Inhibition of SK Channels by M1 Receptors
Negative_regulation (Inhibition) of Negative_regulation (Inhibition) of PKC
5) Confidence 0.11 Published 2010 Journal Neuron Section Body Doc Link PMC3003154 Disease Relevance 0 Pain Relevance 0.03
in the presence/absence of the FP receptor antagonist (AL8810), EP2 receptor antagonist (AH6809), EP4 receptor antagonist (ONOAE2227), PLC inhibitor (U73122), PKA inhibitor (4C3MQ), PKC inhibitor (GF109203x), EGFR kinase inhibitor (AG1478) or ERK1/2 inhibitor (PD98059) for 4 h.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of PKC associated with antagonist
6) Confidence 0.04 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox